Terms: = Leukemia AND PIM1, PIM, 5292, ENSG00000137193, P11309 AND Treatment
120 results:
1. pim Kinases as Potential Biomarkers and Therapeutic Targets in Inflammatory Arthritides.
Assirelli E; Ciaffi J; Scorcu V; Naldi S; Brusi V; Mancarella L; Lisi L; Pignatti F; Ursini F; Neri S
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542097
[TBL] [Abstract] [Full Text] [Related]
2. pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
Lee JK; Chatterjee A; Scarpa M; Bailey CM; Niyongere S; Singh P; Mustafa Ali MK; Kapoor S; Wang Y; Silvestri G; Baer MR
Cancer Res Commun; 2024 Feb; 4(2):431-445. PubMed ID: 38284896
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive Insights that Targeting pim for Cancer Therapy: Prospects and Obstacles.
Chen L; Mao W; Ren C; Li J; Zhang J
J Med Chem; 2024 Jan; 67(1):38-64. PubMed ID: 38164076
[TBL] [Abstract] [Full Text] [Related]
4. KZ02 enhances the radiosensitivity of BRAF-mutated CRC in vitro and in vivo.
Guo Y; Li X; Yuan R; Ren J; Huang Y; Yu Y; Tian H
Eur J Pharmacol; 2023 Nov; 959():176060. PubMed ID: 37775019
[TBL] [Abstract] [Full Text] [Related]
5. Phase 1/2 Study of the Pan-pim Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.
Patel MR; Donnellan W; Byrne M; Asch AS; Zeidan AM; Baer MR; Fathi AT; Kuykendall AT; Zheng F; Walker C; Cheng L; Marando C; Savona MR
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):674-686. PubMed ID: 37290996
[TBL] [Abstract] [Full Text] [Related]
6. Targeting BET Proteins Downregulates miR-33a To Promote Synergy with pim Inhibitors in CMML.
Letson CT; Balasis ME; Newman H; Binder M; Vedder A; Kinose F; Ball M; Kruer T; Quintana A; Lasho TL; Finke CM; Almada LL; Grants JM; Zhang G; Fernandez-Zapico ME; Gaspar-Maia A; Lancet J; Komrokji R; Haura E; Sallman DA; Reuther GW; Karsan A; Rix U; Patnaik MM; Padron E
Clin Cancer Res; 2023 Aug; 29(15):2919-2932. PubMed ID: 37223910
[TBL] [Abstract] [Full Text] [Related]
7. pim2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma.
Haas M; Caron G; Chatonnet F; Manenti S; Alaterre E; Devin J; Delaloy C; Bertolin G; Viel R; Pignarre A; Llamas-Gutierrez F; Marchalot A; Decaux O; Tarte K; Delpy L; Moreaux J; Fest T
Blood; 2022 Apr; 139(15):2316-2337. PubMed ID: 35108359
[TBL] [Abstract] [Full Text] [Related]
8. Discovery of Dual CDK6/pim1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the treatment of Acute Myeloid leukemia.
Yuan K; Ji M; Xie S; Qiu Z; Chen W; Min W; Xia F; Zheng M; Wang X; Li J; Hou Y; Kuang W; Wang L; Gu W; Li Z; Yang P
J Med Chem; 2022 Jan; 65(1):857-875. PubMed ID: 34958208
[TBL] [Abstract] [Full Text] [Related]
9. Genetic ablation of pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models.
Dutta A; Nath D; Yang Y; Le BT; Rahman MF; Faughnan P; Wang Z; Stuver M; He R; Tan W; Hutchison RE; Foulks JM; Warner SL; Zang C; Mohi G
Leukemia; 2022 Mar; 36(3):746-759. PubMed ID: 34741118
[TBL] [Abstract] [Full Text] [Related]
10. Mesenchymal stem cell conditioned medium attenuates oxidative stress injury in hepatocytes partly by regulating the miR-486-5p/pim1 axis and the TGF-β/Smad pathway.
Ma N; Li S; Lin C; Cheng X; Meng Z
Bioengineered; 2021 Dec; 12(1):6434-6447. PubMed ID: 34519263
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic and immunomodulatory effects of pim1 in colorectal carcinoma.
Zhou Y; Zhou Y; Liu S; Wang J; Ji R; Yan X
J BUON; 2021; 26(2):513-520. PubMed ID: 34077000
[TBL] [Abstract] [Full Text] [Related]
12. Overexpression of microRNA‑486 affects the proliferation and chemosensitivity of mesothelioma cell lines by targeting
Pinelli S; Alinovi R; Poli D; Corradi M; Pelosi G; Tiseo M; Goldoni M; Cavallo D; Mozzoni P
Int J Mol Med; 2021 Jun; 47(6):. PubMed ID: 33955505
[TBL] [Abstract] [Full Text] [Related]
13. Effects of pim3 in prognosis of colon cancer.
Zhou Y; Zhou YN; Liu SX; Wang J; Ji R; Yan X
Clin Transl Oncol; 2021 Oct; 23(10):2163-2170. PubMed ID: 33928496
[TBL] [Abstract] [Full Text] [Related]
14. Therapeutic Efficacy of Combined JAK1/2, Pan-pim, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.
Rampal RK; Pinzon-Ortiz M; Somasundara AVH; Durham B; Koche R; Spitzer B; Mowla S; Krishnan A; Li B; An W; Derkach A; Devlin S; Rong X; Longmire T; Eisman SE; Cordner K; Whitfield JT; Vanasse G; Cao ZA; Levine RL
Clin Cancer Res; 2021 Jun; 27(12):3456-3468. PubMed ID: 33782031
[TBL] [Abstract] [Full Text] [Related]
15. pim kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
[TBL] [Abstract] [Full Text] [Related]
16. Design and synthesis of a novel mitochondria-targeted osteosarcoma theranostic agent based on a pim1 kinase inhibitor.
Yi X; Cao Z; Yuan Y; Li W; Cui X; Chen Z; Hu X; Yu A
J Control Release; 2021 Apr; 332():434-447. PubMed ID: 33662457
[TBL] [Abstract] [Full Text] [Related]
17. A phase I, dose-escalation study of oral pim447 in Japanese patients with relapsed and/or refractory multiple myeloma.
Iida S; Sunami K; Minami H; Hatake K; Sekiguchi R; Natsume K; Ishikawa N; Rinne M; Taniwaki M
Int J Hematol; 2021 Jun; 113(6):797-806. PubMed ID: 33638035
[TBL] [Abstract] [Full Text] [Related]
18. IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment.
Shen Y; Crassini K; Fatima N; O'Dwyer M; O'Neill M; Christopherson RI; Mulligan SP; Best OG
Blood Adv; 2020 Oct; 4(20):5093-5106. PubMed ID: 33085757
[TBL] [Abstract] [Full Text] [Related]
19. pim1 Promotes Survival of Cardiomyocytes by Upregulating c-Kit Protein Expression.
Ebeid DE; Firouzi F; Esquer CY; Navarrete JM; Wang BJ; Gude NA; Sussman MA
Cells; 2020 Aug; 9(9):. PubMed ID: 32878131
[TBL] [Abstract] [Full Text] [Related]
20. Propofol Protects Against TNF-α-induced Blood-brain Barrier Disruption via the pim-1/eNOS/NO Pathway.
Lu Y; Xu Z; Shen F; Lin R; Li H; Lv X; Liu Z
Curr Neurovasc Res; 2020; 17(4):471-479. PubMed ID: 32819257
[TBL] [Abstract] [Full Text] [Related]
[Next]
